168 related articles for article (PubMed ID: 16114026)
1. Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.
Skogseid IM; Røislien J; Claussen B; Kerty E
Mov Disord; 2005 Dec; 20(12):1604-9. PubMed ID: 16114026
[TBL] [Abstract][Full Text] [Related]
2. Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status.
Molho ES; Agarwal N; Regan K; Higgins DS; Factor SA
Mov Disord; 2009 Jul; 24(9):1384-7. PubMed ID: 19441129
[TBL] [Abstract][Full Text] [Related]
3. Working capacity and cervical dystonia.
Martikainen KK; Luukkaala TH; Marttila RJ
Parkinsonism Relat Disord; 2010 Mar; 16(3):215-7. PubMed ID: 19660976
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cervical dystonia with botulinum toxin.
Jankovic J
Mov Disord; 2004 Mar; 19 Suppl 8():S109-15. PubMed ID: 15027062
[TBL] [Abstract][Full Text] [Related]
5. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
6. The position of the head in space: a kinematic analysis in patients with cervical dystonia treated with botulinum toxin.
Albani G; Bulgheroni MV; Mancini F; Mauro A; Fundarò C; Pacchetti C; Sandrini G; Nappi G
Funct Neurol; 2001; 16(2):135-41. PubMed ID: 11495419
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation.
Racette BA; McGee-Minnich L; Perlmutter JS
Clin Neuropharmacol; 1999; 22(6):337-9. PubMed ID: 10626093
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism.
Bonanni L; Thomas A; Varanese S; Scorrano V; Onofrj M
Mov Disord; 2007 Oct; 22(14):2097-103. PubMed ID: 17685467
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
Slawek J; Friedman A; Potulska A; Krystkowiak P; Gervais C; Banach M; Ochudlo S; Budrewicz S; Reclawowicz D; Rynkowski M; Opala G
Funct Neurol; 2007; 22(2):95-100. PubMed ID: 17637212
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.
Berman B; Seeberger L; Kumar R
Mov Disord; 2005 Feb; 20(2):233-7. PubMed ID: 15455449
[TBL] [Abstract][Full Text] [Related]
11. Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients.
Maia FM; Kanashiro AK; Chien HF; Gonçalves LR; Barbosa ER
Parkinsonism Relat Disord; 2010 Jan; 16(1):8-11. PubMed ID: 19589716
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.
Haussermann P; Marczoch S; Klinger C; Landgrebe M; Conrad B; Ceballos-Baumann A
Mov Disord; 2004 Mar; 19(3):303-8. PubMed ID: 15022184
[TBL] [Abstract][Full Text] [Related]
13. Fast voluntary neck movements in patients with cervical dystonia: a kinematic study before and after therapy with botulinum toxin type A.
Gregori B; Agostino R; Bologna M; Dinapoli L; Colosimo C; Accornero N; Berardelli A
Clin Neurophysiol; 2008 Feb; 119(2):273-80. PubMed ID: 18063411
[TBL] [Abstract][Full Text] [Related]
14. Age-related botulinum toxin effects on muscle fiber conduction velocity in non-injected muscles.
Lange F; van Weerden TW; van der Hoeven JH
Clin Neurophysiol; 2007 Nov; 118(11):2398-403. PubMed ID: 17897878
[TBL] [Abstract][Full Text] [Related]
15. Adult cases of congenital muscular torticollis successfully treated with botulinum toxin.
Bouchard M; Chouinard S; Suchowersky O
Mov Disord; 2010 Oct; 25(14):2453-6. PubMed ID: 20976740
[TBL] [Abstract][Full Text] [Related]
16. [Clinical and psychological factors influencing the efficacy of botulinum toxin in the treatment of hemifacial spasm and blepharospasm].
Burbaud P; Arnaud A; Burbaud A; Lagueny A
J Fr Ophtalmol; 1995; 18(12):751-7. PubMed ID: 8745707
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin: historical perspective and potential new indications.
Jankovic J; Brin MF
Muscle Nerve Suppl; 1997; 6():S129-45. PubMed ID: 9826986
[TBL] [Abstract][Full Text] [Related]
18. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.
Jankovic J; Hunter C; Dolimbek BZ; Dolimbek GS; Adler CH; Brashear A; Comella CL; Gordon M; Riley DE; Sethi K; Singer C; Stacy M; Tarsy D; Atassi MZ
Neurology; 2006 Dec; 67(12):2233-5. PubMed ID: 17190952
[TBL] [Abstract][Full Text] [Related]
19. Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients.
Lo SE; Rosengart AJ; Novakovic RL; Kang UJ; Shah DN; Khan MA; Dalvi A; Goldenberg FD; Macdonald RL; Frank JI
Neurocrit Care; 2005; 3(2):139-45. PubMed ID: 16174883
[TBL] [Abstract][Full Text] [Related]
20. Focal dystonia in musicians: treatment strategies and long-term outcome in 144 patients.
Jabusch HC; Zschucke D; Schmidt A; Schuele S; Altenmüller E
Mov Disord; 2005 Dec; 20(12):1623-6. PubMed ID: 16078237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
